PHusis Therapeutics
Dr. Chaplin is former Chief Scientific Officer of OXiGENE where he guided lead agent ZYBRESTAT from discovery to Phase III trials and OXi4503 into Phase I. At OXiGENE he developed productive international drug discovery and research collaborations with numerous academic institutions in the USA, Canada and Europe and was closely involved in five financings raising over 200 million dollars. Prior to that Dr. Chaplin oversaw integration of worldwide oncology research operations following merger of RPR and HMR to form AVENTIS and was responsible for their Global Oncology research operations covering discovery through end of Phase I. Additionally he co-founded Angiogene Pharmaceuticals and licensed its lead agent to AstraZeneca.
This person is not in the org chart
This person is not in any teams
This person is not in any offices